• Pliant Therapeutics named David Raben as chief medical officer, effective Sept. 30, 2026.
• Raben most recently served as chief medical officer at Bicara Therapeutics, leading clinical development of ficerafusp alfa (BCA101).
• He previously held senior oncology development roles at Amgen, led late-stage oncology programs at Genentech, and was a professor at the University of Colorado Cancer Center.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609301610PRIMZONEFULLFEED9837266) on September 30, 2026, and is solely responsible for the information contained therein.